© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Olaratumab Maleate stands out as a key raw material in pharmaceutical development, especially within cancer research. Developed through targeted synthesis, this compound has served in targeted therapies, notably as an antibody modulator. It belongs to the broader class of monoclonal antibody therapeutics, with a structure engineered for selective binding to platelet-derived growth factor receptor alpha (PDGFR-α). Leveraging this selectivity, Olaratumab Maleate offers more than just a physical presence; it carries the consequence of extensive research in both molecular design and medicinal chemistry.
Olaratumab Maleate presents as an off-white to white solid. In labs, the material can arrive in two main forms: either as a fine powder or as slightly larger crystalline flakes. The solid form allows for straightforward measurement and stability checks. Chemists often keep a close eye on specific density, which for Olaratumab Maleate, hovers around 1.3 to 1.4 g/cm3 at room temperature. Handling this chemical means gloves and proper ventilation—not because the appearance is ominous, but for the safety standard expected with bioactive materials.
At the molecular level, Olaratumab Maleate combines a large antibody (Olaratumab) with a maleic acid salt. The structure hints at a dense backbone built on immunoglobulin chains, each with characteristic folding and disulfide bridges. The formula can get unwieldy, since monoclonal antibodies host thousands of atoms, centrally carbon, hydrogen, oxygen, nitrogen, and sulfur. Addition of maleate confers solubility in aqueous solutions and slight acidity, properties that researchers find useful in formulation and injection preparations.
In the realm of regulations and logistics, the HS Code functions as the entry ticket for import and export procedures. Olaratumab Maleate, as an active pharmaceutical ingredient (API), takes a position under 2933 or 3002 groups, depending on specific preparation and purity. A pharmaceutical raw material like this faces scrutiny during customs checks, and correct documentation speeds up the entire process. Clear, accurate assignment within the Harmonized System (HS) prevents delays and ensures safe handling from manufacture to end user.
Within R&D spaces and production floors, Olaratumab Maleate offers stability in both flake and powder forms. Powders can clump under humidity, so sealed, dry containers matter. Each batch features traceable labeling, showing batch number, production date, and storage conditions—especially light and temperature control. In solution, Olaratumab Maleate sits dissolved at specified concentrations, commonly between 10 mg/mL and 100 mg/mL, though research protocols might shift these levels. Good Manufacturing Practice (GMP) standards call for clarity and absence of visible particles in solutions to avoid problems in downstream applications.
Olaratumab Maleate carries the safety expectations of both an antibody and a chemical salt. Though not a caustic or highly volatile compound, accidental inhalation or contact still poses health risks, including skin or eye irritation. Laboratory teams depend on up-to-date Material Safety Data Sheets (MSDS), outlining personal protective equipment (PPE) requirements. In smaller doses, toxicity remains low, but improper disposal or uncontrolled release would still contravene workplace safety and environmental guidelines. For storage, secure, labeled containers in a cool, dark place give the best chance of maintaining purity and potency over time.
Olaratumab Maleate's main claim to fame comes from its role in oncology clinical trials. Used as a leading candidate for advanced treatment against soft tissue sarcoma, research highlighted both its promise and challenges. As studies advanced, new questions about efficacy and safety shifted its relevance, but its history reflects the unpredictable nature of medical innovation. Even where clinical results did not lead to long-term approvals, the production and handling standards developed for this material set templates for subsequent therapeutics. Practical lessons here range from sterile filtration, stability testing, all the way to formulation with human safety in mind.
Looking ahead, improvements around Olaratumab Maleate rest on a solid foundation. Better characterization methods—using advanced spectroscopy and chromatography—expand the window of quality assessment. Packaging innovations, smart labeling, and tight temperature controls cut the risk of material loss or misidentification. While no miracle solutions appear overnight in pharmaceutical logistics, discipline in adherence to international safety and handling standards holds the industry together. Collaborative reporting of incidents or near-misses keeps the bar high, and this kind of transparency breeds trust from patients, regulators, and colleagues alike.
